Glybera (alipogene tiparvovec) was the world’s first AAV-based gene therapy to gain regulatory approval for commercialization from the European Medicines Agency in 2012.211 Glybera is an AAV1-based gene therapy that delivered lipoprotein lipase (LPL) to patients with LPL deficiency.212 It was also infamous for gaining the moniker of “the world’s first million-dollar drug.” Due to low demand and its high cost, Glybera was withdrawn from European markets and has yet to gain approval in other countries. This evidence concerns the gene LPL and hyperinsulinemic hypoglycemia, familial, 4.